Phase 2Completed
Aleniglipron Phase 2 Body Composition Study
A Phase 2, Randomized, Double-blind, Placebo-controlled, Study Evaluating the Effects of Aleniglipron (GSBR-1290) on Body Composition in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2)
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics (Industry)
- Enrolment
- 71 enrolled
- Conditions
- Obesity, Overweight, or Chronic Weight Management
- Interventions
- aleniglipron or placebo
- Ages
- adults, older adults
- Registry
- NCT07169942
Full record on ClinicalTrials.gov
From the registry
This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 44 weeks of treatment.
Primary outcomes
- Percent change in total body fat mass by DXA
History
Last registry update
Study completion
Primary completion
Registered
Started